ClinicalTrials.Veeva

Menu

Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)

Indiana University logo

Indiana University

Status and phase

Enrolling
Phase 3
Phase 2

Conditions

Sickle Cell Disease

Treatments

Drug: Placebo
Drug: zinc sulfate

Study type

Interventional

Funder types

Other

Identifiers

NCT06561061
2023-841

Details and patient eligibility

About

A randomized double-blinded placebo-controlled trial of zinc to reduce the incidence of severe or invasive infections in Ugandan children with sickle cell anemia (SCA)

Full description

The study will be a randomized, placebo-controlled, double blind clinical trial in which 100 Ugandan children 1.00-4.99 years of age with SCA will receive zinc (20 mg oral dispersible tablet daily) or placebo (identical to zinc in appearance) for 6 months. The primary study outcome will be incidence of infection (all causes).

Enrollment

100 estimated patients

Sex

All

Ages

12 to 59 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Documented sickle cell anemia (HbSS supported by hemoglobin electrophoresis)
  • Age range of 1.00-4.99 years, inclusive, at the time of enrollment
  • Weight at least 5.0 kg at the time of enrollment
  • Willingness to comply with all study-related treatments, evaluations, and follow-up
  • Children whose parents or guardians give full written informed consent

Exclusion criteria

  • Known other chronic medical condition (e.g., HIV, malignancy, active clinical tuberculosis)
  • Severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or height for age z-score <-3, using WHO growth standards)
  • Absolute neutropenia (absolute neutrophil count <500)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

100 participants in 2 patient groups, including a placebo group

Zinc
Experimental group
Description:
Dispersible zinc sulfate tablet (20 mg)
Treatment:
Drug: zinc sulfate
Placebo
Placebo Comparator group
Description:
Dispersible identical placebo tablet
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Isaac Birungi; Ruth Namazzi, MBChB

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems